La catena delle opzioni mostra i dati chiave delle opzioni azionarie di BioVie a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per BioVie..

BioVie (NASDAQ:BIVI) Azioni, Catena delle Opzioni

BioVie

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

BioVie Inc

BIVICTRIX THERAPEUTICS PL by BIVICTRIX THERAPEUTICS PLC

Wells Fargo analyst Michael Berg maintains CSG Systems Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGS#NASDAQ">CSGS</a>) with a Equal-Weight and lowers the price target from $65 to $58.

News

Price Target

Analyst Ratings

CSGS

Wells Fargo Maintains Equal-Weight on CSG Systems Intl, Lowers Price Target to $58

GSRTR

Trading Halt: Halt status updated at 8:30:00 AM ET: Quotation Resumption: News and Resumption Times

Wells Fargo analyst Michael Berg maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Overweight and lowers the price target from $55 to $40.

BRZE

Wells Fargo Maintains Overweight on Braze, Lowers Price Target to $40

Comerica Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/quote/CMA/earnings">first quarter on Monday.</a>
The company posted quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.15 per share. The company reported quarterly sales of $829.00 million which missed the analyst consensus estimate of $831.34 million.
Comerica shares dipped 4.4% to close at $50.60 on Monday.
These analysts made changes to their price targets on Comerica following earnings announcement.
<ul>
<li>JP Morgan analyst Anthony Elian downgraded Comerica from Neutral to Underweight and lowered the price target from $64 to $52.</li>
<li>Baird analyst David George maintained Comerica with an Outperform rating and lowered the price target from $80 to $75.</li>
<li>Wells Fargo analyst Mike Mayo maintained the stock with an Equal-Weight rating and cut the price target from $67 to $55.</li>
</ul>
Considering buying CMA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22082651/image-46-1024x603.png" alt="" class="wp-image-881760" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22082651/image-46-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22082651/image-46-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22082651/image-46-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/22082651/image-46.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

Comerica Analysts Slash Their Forecasts After Q1 Earnings

Wells Fargo analyst Andrew Bauch maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Underweight and lowers the price target from $57 to $43.

BILL

Wells Fargo Maintains Underweight on BILL Holdings, Lowers Price Target to $43

WIIM

CALX

Calix shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates. Additionally, the company announced an authorized increase to its stock repurchase program.

Wells Fargo analyst Christian Wetherbee maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Equal-Weight and lowers the price target from $260 to $220.

Wells Fargo Maintains Equal-Weight on FedEx, Lowers Price Target to $220

GSRT

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Wells Fargo analyst Mike Mayo maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Equal-Weight and lowers the price target from $58 to $47.

ZION

Wells Fargo Maintains Equal-Weight on Zions Bancorp, Lowers Price Target to $47

Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares
LAVAL, QC / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 22, 2025 / Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>)(TSX:<a class="ticker" href="https://www.benzinga.com/stock/BHC#TSX">BHC</a>) (the "Company" or "Bausch Health") today announced that it has filed a supplement (the "Proxy Statement Supplement") to its proxy statement dated April 2, 2025 (the "Proxy Statement") in respect of the Company's upcoming annual general meeting of shareholders on May 13, 2025. The Company is updating the Proxy Statement to disclose, in addition to the 34,721,118 common shares reported as being beneficially owned (9.4%), Mr. Carl C. Icahn and his affiliates (collectively, "Icahn") had entered into cash-settled equity swap agreements covering 90,720,000 of the Company's common shares (24.6%), with a single maturity date of February 28, 2028. Taken together Icahn now has an economic interest covering approximately 34% of the Company's outstanding common shares.

TSX:BHC

Bausch Health Announces Filing Of Supplement To Proxy Statement Revealing Carl Icahn's Cash-Settled Equity Swaps Covering 90.72M Shares, Boosting Economic Interest To 34% Of Common Shares

Wells Fargo analyst Mike Mayo maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Equal-Weight and lowers the price target from $67 to $55.

Wells Fargo Maintains Equal-Weight on Comerica, Lowers Price Target to $55

Contracts

OPTX

Syntec Optics Secures $5.2M On New Orders For Defense Night Vision Goggle Optics

Wells Fargo analyst Elyse Greenspan maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Equal-Weight and raises the price target from $69 to $70.

Wells Fargo Maintains Equal-Weight on WR Berkley, Raises Price Target to $70

New 5 MW Hosting Deal Highlights Growing Demand for Sustainable Bitcoin Infrastructure
Soluna Holdings, Inc. ("Soluna" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, announced today that it has signed a two-year hosting agreement with Blockware, one of North America's leading crypto mining infrastructure and services providers.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250422128504/en/">https://www.businesswire.com/news/home/20250422128504/en/</a>
Soluna Signs Deal with Blockware at Project Dorothy 2, Expanding Bitcoin Hosting Business
Under the terms of the agreement, Blockware will deploy approximately 1,500 of its next-generation S21+ mining units at Soluna's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.solunacomputing.com%2Fnews%2Fsoluna-powers-up-project-dorothy-2%2F&amp;esheet=54241444&amp;newsitemid=20250422128504&amp;lan=en-US&amp;anchor=Project+Dorothy+2&amp;index=1&amp;md5=7e369b26be90ecf46ed06a091c0ba74c">Project Dorothy 2</a> data center in Texas. The deployment, targeting an initial deployment of 5 megawatts (MW), began on April 21, 2025, with operations expected to fully ramp up by June 1, 2025. Blockware anticipates deploying 250 PH/s to 350 PH/s at the site.

SLNH

Soluna Has Signed A 2-Year Hosting Agreement With Blockware; Blockware Will Deploy ~1,500 Of Its Next-generation S21+ Mining Units At Soluna's Project Dorothy 2 Data Center In Texas

Syntec Optics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>), a leading provider of technology to defense, biomedical, communications and consumer industry leaders, today announced it has secured orders totaling nearly $5.2 million so far this year for optics and optomechanicals supporting the latest generation of advanced night vision goggles used in the U.S. defense to keep our soldiers out of harm's way. Syntec's mission-critical optics make the helmet-mounted goggle lighter to reduce neck trauma for soldiers.
As a strong start to the year, Syntec has already delivered nearly $0.9M in product. Syntec will continue to deliver and build upon its multi-year involvement in this key defense program, where it has supplied vital low-weight, high-performance manufacturing technology since initial development phases began in 2018. The nearly $5.2 million in recent orders in 2025 highlights Syntec's expanded role in providing a comprehensive suite of products crucial for the functionality of advanced binocular systems, known for enhancing situational awareness and incorporating fused thermal imaging capabilities.
"We are pleased to see continued strong demand for this critical night vision program, " said Matt Carey, head of Business Development and Delivery at Syntec Optics. "This demonstrates the ongoing trust placed in Syntec's ability to deliver products that meet the rigorous performance standards required for national defense."
Mike Ransford, Site Leader at Syntec Optics, commented, "The consistent order flow, now totaling close to $5.2 million this year, corresponds with the active fielding and sustained need for these advanced night vision capabilities. Our ability to provide a broad spectrum of products, from foundational optics to complex sub-assemblies, positions Syntec as a comprehensive partner for this long-term program."

Syntec Optics Secures Orders Totaling ~$5.2M So Far This Year For Optics And Optomechanicals Supporting The Latest Generation Of Advanced Night Vision Goggles Used In  U.S. Defense

Wells Fargo analyst Roger Read maintains Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) with a Equal-Weight and raises the price target from $45 to $46.

Wells Fargo Maintains Equal-Weight on Ovintiv, Raises Price Target to $46

Baird analyst David George maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Neutral and lowers the price target from $58 to $55.

Baird Maintains Neutral on Zions Bancorp, Lowers Price Target to $55

Wells Fargo analyst Zachary Fadem maintains Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Equal-Weight and lowers the price target from $52 to $45.

CAKE

Wells Fargo Maintains Equal-Weight on Cheesecake Factory, Lowers Price Target to $45

<a href="https://www.globenewswire.com/Tracker?data=8veCI3g1em0T5GGwxfmnLVIVtYKMBB8pXLtaciIKxM9A0i2WsW8FFPkjcfoqrnlwbi26Zn5XKQ2SR-yoxGrPZB0HR-TJFI44CC-rcBC4XiY=">CERo Therapeutics Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction.
The gross proceeds to CERo from the offering are expected to be up to $8 million, including $5 million expected to be received through the investment of securities at the first closing, and up to $3 million of cash that may be funded at one or more additional closings, at the election of the investors. &nbsp;CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly.&nbsp; The proceeds will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway.&nbsp;

Financing

CERO

CERo Therapeutics Announces Up To $8M In Series D Financing

Construction on Auto Clubhouse Charlotte is Expected to Commence in Q3 2025
Lantana, FL, April 22, 2025 (GLOBE NEWSWIRE) -- JFB Construction Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFB#NASDAQ">JFB</a>), a construction company focused on commercial, retail, and residential property development, today announced plans to commence, in Q3 2025, the largest single commercial construction project in company history. Pursuant to the Agreement, JFB will serve as the prime contractor to manage design and construction of Auto Clubhouse in Charlotte, North Carolina, a 103,000 square foot warehouse for car storage that contains 42 luxury auto condo bays and a 40,000 square foot storage building for luxury vehicles.
"Our general commercial construction division that has been a key component of our past growth will continue to be instrumental in the future growth of our business which represents a significant portion of our total revenue," said CEO Joseph F. Basile, III. "The Auto Clubhouse project is our largest single commercial / industrial construction project to date, in which we will serve as the prime contractor. This is a 103,000 square foot warehouse and condos to store luxury vehicles. We believe that this industrial project will open the doors for more industrial projects in the future. Our general commercial construction division will continue to focus on the Southern Atlantic region of the United States in the short to mid-term, focusing on regions where we forecast continued state-to-state migration and expanding population growth."
Auto Clubhouse is an exclusive community of affluent high net-worth auto enthusiasts looking to store their luxury cars. The community offers built-to-suit customizable garages, which will be also constructed by JFB Construction, with high-end security, a members' clubhouse and additional benefits.&nbsp;The first Auto Clubhouse is under construction in Jupiter, Florida. The Company is currently in planning stage for the building of additional Auto Clubhouse locations in Dallas, Texas, Scottsdale, Arizona, and Sarasota, Florida.

JFB Construction Holdings Announces $15M Industrial Construction Of Auto Clubhouse In Charlotte, North Carolina. Project Is Expected To Commence In Q3 2025

Press Releases

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Health Care

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering

BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

Legal

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions Inc. (NASDAQ: MSS)

ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions Survive Motions to Dismiss

Comments

BioVie

BioVie (BIVI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO